What is this study trying to find out about ATTR amyloidosis and carpal tunnel syndrome?

This study aims to find out how common ATTR amyloidosis is in patients who had surgery for carpal tunnel syndrome and to monitor those with the condition for heart involvement. Researchers will follow patients over 10 years to learn about the development of cardiac amyloidosis. The study is sponsored by Helse Møre og Romsdal HF.

Who may be eligible for this ATTR amyloidosis clinical trial?

Adults older than 50 years for males and older than 60 years for females who have had carpal tunnel syndrome surgery at Ålesund Hospital may be eligible. Participants must speak Norwegian and not have cardiac disease at the time of surgery. Please review eligibility criteria for more details.

Is there any cost to participate in this ATTR amyloidosis clinical trial?

Study-related care, including all examinations and follow-up visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Age: 50Years +

All Genders

ID06458374

Study of ATTR Cardiac Amyloidosis in Patients Over 50 with Carpal Tunnel Syndrome Surgery Long-Term Follow-Up for 10 Years to Monitor Heart Health

Led by Helse Møre og Romsdal HF · Updated on 2026-08-12

180

Participants Needed

Research Sites

260 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to study patients who have undergone surgery for carpal tunnel syndrome CTS at lesund Hospital to identify the presence of ATTR amyloidosis through biopsy. The study focuses on patients with biopsy-confirmed ATTR amyloidosis, assessing whether they have cardiac amyloidosis and monitoring them closely over a long term. The study is observational and plans to follow participants for up to 10 years to understand the frequency of ATTR in CTS and cardiac involvement. Patients with biopsy-proven ATTR amyloidosis will undergo standard examinations recommended by guidelines, including 99mTcDPD SPECT CT, echocardiography, ECG, Holter monitoring, genetic testing for variant and wild type ATTR, laboratory tests, and CMRI when indicated. Light chain disease will be excluded. All patients will be monitored at least annually following established guidelines, and those developing cardiac amyloidosis will receive standard treatments approved by Norwegian authorities. Participants will be followed clinically and with echocardiography yearly for at least 10 years. Assessments include imaging, genetic testing, and laboratory evaluations to track disease progression and cardiac involvement. The primary outcome measures are the frequency of ATTR in CTS within 2 years and cardiac involvement in patients with biopsy-confirmed ATTR over 10 years. This extended follow-up aims to provide comprehensive data on the long-term impact of ATTR amyloidosis in this selected population.

CONDITIONS

Brief Title

ATTR Cardiac Amyloidosis in a Selected Population

Who Can Participate

Age: 50Years +

All Genders

Eligibility Criteria

You may qualify if you...

Male older than 50 years
Female older than 60 years
Have had carpal tunnel syndrome surgery at Ålesund Hospital

You will not qualify if you...

Have not given consent
Do not speak Norwegian
Carpal tunnel syndrome caused by trauma or rheumatic disease
Cannot be followed for more than 5 years due to other medical conditions
Have cardiac disease at the time of carpal tunnel syndrome surgery

Research Team

Torstein Hole, Professor, MD, PhD

Jørn A Lillebø, consultant cardiology, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here